investors.chromadex.comChromaDex Corp. Investor Relations

Investor Relations Overview Science Overview Ongoing Studies Notable Scientific Research EventsPresentations Stock Stock QuoteChart Analyst Coverage Financial Reports Financial Results SEC Filings Governance Governance Documents Leadership Committee Composition Contact the Board Investor Resources Contacts Email Alerts FAQs Investor Documents RSS Feeds Links to Elysium Related Litigation Market Surveillance News Investor Menu Overview Science Overview Ongoing Studies Notable Scientific Research EventsPresentations Stock Stock QuoteChart Analyst Coverage Financial Reports Financial Results SEC Filings Governance Governance Documents Leadership Committee Composition Contact the Board Investor Resources Contacts Email Alerts FAQs Investor Documents RSS Feeds Links to Elysium Related Litigation Market Surveillance News CEO Message Read Rob's Op-Ed in Natural Products Insider: A Self-Regulated Supplement Industry as a Path to Responsible Innovation Meet our Scientific Advisory Board We are a science-based integrated nutraceutical company devoted to improving the way people age.We are a global bioscience company dedicated to healthy aging. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN ® nicotinamide riboside, sold directly to consumers as TRU NIAGEN ® , is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN ® is helping the world AGE BETTER ® .The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. The Company delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen® available at www.truniagen.com and through partnerships with global retailers and distributors. The Company also develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Company further offers natural product fine chemicals, known as phytochemicals, and related research and development services. Key Investment Highlights: Leader in the rapidly growing NAD+ market for healthy aging Large addressable market - $170B global TAM in vitamins and supplements (+5% growth annually) Proven and proprietary NAD+ boosting supplement (Tru Niagen®) - ~$60 million in sales in 2021 (+79% CAGR (1) ) Strategic partnerships to grow Tru Niagen® global distribution footprint with focus on Asia Pacific region Independent scientific research supporting benefits of proprietary ingredient with 20 clinical trials Significant opportunity driven by expanded benefit claims, including therapeutic potential in pharmaceutical field Strong intellectual property portfolio with 30+ patents for Niagen® and other NAD precursors Strengthening financial position with cash flow break - even or better anticipated in Q4 2022Global authority on NAD+ with significant market opportunity across wide-ranging categories ($500B+ TAM in human and pet nutrition, cosmetics and pharmaceuticals) Proven and proprietary NAD+ boosting supplement (Tru Niagen®) with $70+ million in sales in 2023 (+52% CAGR (1) ) and over $10 million of Niagen® ingredient sales in 2023 to food nutrition and supplement companies Strategic partnerships to grow Tru Niagen® global distribution footprint with focus on Asia Pacific Independent scientific research supporting benefits of proprietary ingredient with 30+ published clinical studies and $100MM+ of third-party research Strong intellectual property portfolio with 80+ patents for Niagen® and other NAD precursors Strong financial position, with positive $1.9 million Adjusted EBITDA in 2023 (1) CAGR calculated for the 2017-2023 calendar years period 1 PROVEN AND PROPRIETARY NAD+ BOOSTING SUPPLEMENT In March 2017 ChromaDex began a strategic shift from an ingredient and testing company with the long-term goal of building its new consumer product, TRU NIAGEN ® , into a global brand. The company has since expanded retail distribution into four new international markets and has signed supply agreements with strong global partners, including Nestlé Health Science and A.S. Watson Group. ( See link to Nestlé Health Science press release ) and ( See link to latest A.S. Watson Group press release )Total 2020 net sales of $59 million with $47 million of Tru Niagen® net sales Tru Niagen® is the most efficient way to safely elevate NAD+ Safety profile backed by 15 clinical trials and global regulatory approvals Strong IP protection with 30+ owned or licensed patents $75MM+ of third-party research on Niagen®2 SIGNIFICANT OPPORTUNITY DRIVEN BY TRENDS IN HEALTHWELLNESS Global anti-aging market of ~$410 billion with dietary supplements growing 6% (1) Tru Niagen® gaining share in healthy aging and fitness categories; potential to expand to larger addressable markets Exploring adjacent categories for Niagen® such as pet and infant nutrition (1)ChromaDex estimates. See latest Investor Presentation for details3 EXPANDING GLOBAL DISTRIBUTION AND INTRODUCING NEW PRODUCTS E-commerce represents ~60% of the business today, including North America, Europe, and Asia Expanded to UK and Australia in 2020 Launched in Walmart U.S. in June 2021 Strong blue-chip partners include A.S. Watson, Nestlé Health Science and W.R. Grace, and two new partners in 2021 in H&H Group and Ro4 STRONG MOMENTUM AND FINANCIAL DISCIPLINE Revenue CAGR of +47% and gross margin increase from 48% to 60% since strategic pivot to focus on consumer product, Tru Niagen® (2) Approaching cash flow break-even, as measured by Adjusted EBITDA excluding total legal expense (2)Period from Q1 2017 to Q3 2020. Revenue CAGR of ~40% and gross margin increase from 48% to 60%+ since strategic pivot to focus on consumer product, Tru Niagen® (2) Approaching cash flow break-even, as measured by Adjusted EBITDA excluding total legal expense (3) Investing in brand building and R&D in 2021 given rapid growth in NAD+ market (2) Period from Q1 2017 to Q2 2021. Quarterly sales. (3) Non-GAAP metric.Build a Global Brand In March 2017 ChromaDex began a strategic shift from an ingredient and testing company with the long-term goal of building its new consumer product, TRU NIAGEN ® , into a global brand. The company has since expanded retail distribution into four new international markets and has signed supply agreements with strong global partners, including Nestlé Health Science and A.S. Watson Group. ( See link to Nestlé Health Science press release ) and ( See link to latest A.S. Watson Group press release ) Own the Science As a leader in the growing field of NR and NAD research, ChromaDex continues to build upon and protect its intellectual property, invest in quality research, partner with the world's leading scientists, and educate consumers on the health benefits of NR. ( Notable Scientific Research ) ( Patent Portfolio ) ChromaDex has a strong patent portfolio around TRU NIAGEN ® , with over 16 licensed global patents or patents pending. The lead patent is one that is exclusively licensed from Dartmouth. In September 2018, ChromaDex and the Trustees of Dartmouth College filed a patent infringement complaint in the United States District Court for the District...